Leaders in Pharmaceutical Business Intelligence (LPBI) Group

CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Reason for doing the study
1.3 Key Benefits
1.4 Key Market Segments
1.5 Key Audiences
1.6 Research Methodology

1.6.1 Secondary Research
1.6.2 Primary Research
1.6.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2025

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Historical perspective and current market trends
3.3 SMaRT RNA Technology- A promising Tool To Target Disease Causing RNAs
3.4 Conventional Vs RNA-based therapeutics
3.5 Addressable Market Analysis

3.5.1 DNA based therapeutics
3.5.2 RNA based thearpeutics

3.6 Key Findings

3.6.1 Top Factors Impacting on RNA based therapeutics market
3.6.2 Top Investment Pockets of RNA based therapeutics market
3.6.3 Top winning strategies of RNA based therapeutics market

3.7 Government Regulations

3.7.1 USFDA Perspective
3.7.2 European Union Perspective

3.8 Porter five force model

3.8.1 Bargaining power of buyers (Low)
3.8.2 Bargaining power of suppliers(High)
3.8.3 Threat of new entrants (High)
3.8.4 Threat of substitute products (Moderate)
3.8.5 Intensity of competitive rivalry (Strong)

3.9 Value chain analysis

3.9.1 Primary activities
3.9.2 Support Activities

3.10 Pipeline Review
3.11 Patent Analysis

3.11.1 Patent analysis by geographies(2010-2014)

3.12 Clinical Trials For RNA Based Therapeutics
3.13 Market Dynamics

3.13.1 Drivers

3.13.1.1 Target specificty and selectivity of treatment
3.13.1.2 Strategic Alliances and Funding
3.13.1.3 More intense product focus against platform technology
3.13.1.4 Promising technologies driving the RNA based therapeutics
3.13.1.5 Adoption of virtual drug development models

3.13.2 Restraints

3.13.2.1 Hurdles in drug delivery
3.13.2.2 High cost of research and threat of failure

3.13.3 Opportunities

3.13.3.1 Early commercialization of pipeline therapeutics assists to gain competitive advantage
3.13.3.2 Multifactorial disease targeting

CHAPTER 4 GLOBAL RNA BASED THERAPEUTICS  MARKET BY TECHNOLOGIES, 2013-2020, $MILLION

4.1 Enabling technologies

4.1.1 Microarrays
4.1.2 Labelling
4.1.3 Purification
4.1.4 Linear amplification
4.1.5 qRT-PCR
4.1.6 Inhibition

4.2 Enabled technologies

4.2.1 RNA Interference (RNAi) technologies

4.2.1.1 Market Dynamics

4.2.1.1.1 DRIVERS
4.2.1.1.2 RESTRAINTS
4.2.1.1.3 OPPORTUNITIES

4.2.1.2 Competitive scenario
4.2.1.3 Small interfering RNA (siRNA)
4.2.1.4 MicroRNA (miRNA)
4.2.1.5 Market size & forecast

4.2.2 RNA antisense technologies

4.2.2.1 Market Dynamics

4.2.2.1.1 DRIVERS
4.2.2.1.2 RESTRAINTS
4.2.2.1.3 OPPORTUNITIES

4.2.2.2 Competitive scenario
4.2.2.3 Market size & forecast

CHAPTER 5 GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATIONS, 2013-2020, $MILLION

5.1 Cardiovascular

5.1.1 Global Cardiac Disease Incidences

5.1.1.1 Facts for cardiac diseases

5.1.2 Adoption Drivers
5.1.3 Market Size and Forecast

5.2 Kidney Diseases

5.2.1 Global Renal Disease Incidences
5.2.2 Adoption Drivers
5.2.3 Market Size and Forecast

5.3 Oncology

5.3.1 Global Cancer Incidences
5.3.2 Adoption Drivers
5.3.3 Market Size and Forecast

5.4 Infectious diseases

5.4.1 Global Infectious Disease Incidences

5.4.1.1 Tuberculosis
5.4.1.2 HIV and AIDS

5.4.2 Adoption Drivers
5.4.3 Market Size and Forecast

5.5 Metabolic disorders

5.5.1 Global Metabolic Disorders by Type

5.5.1.1 Obesity
5.5.1.2 Diabetes

5.5.2 Adoption Drivers
5.5.3 Market Size and Forecast

5.6 Others
CHAPTER 6 GLOBAL RNA BASED THERAPEUTICS MARKET BY END USERS, 2013-2020, $MILLION

6.1 Research
6.2 Therapeutics
6.3 Diagnosis

CHAPTER 7 GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013-2020, $MILLION

7.1 North America

7.1.1 United States

7.1.1.1 Pipeline Review
7.1.1.2 Market Trends
7.1.1.3 Competitive scenario
7.1.1.4 Key growth factors and opportunities

7.1.2 Canada

7.1.2.1 Pipeline Review
7.1.2.2 Key market trends
7.1.2.3 Competitive scenario
7.1.2.4 Key growth factors and opportunities

7.2 Europe

7.2.1 Germany

7.2.1.1 Pipeline Review
7.2.1.2 Key market trends
7.2.1.3 Competitive scenario
7.2.1.4 Key growth factors and opportunities

7.2.2 United Kingdom

7.2.2.1 Pipeline Review
7.2.2.2 Key market trends
7.2.2.3 Competitive scenario
7.2.2.4 Key growth factors and opportunities

7.2.3 France
7.2.4 Others

7.3 Asia-Pacific

7.3.1 Pipeline Review
7.3.2 Key market trends
7.3.3 Competitive scenario
7.3.4 Key growth factors and opportunities
7.3.5 Market size and forecast

7.4 LAMEA

7.4.1 Pipeline Review
7.4.2 Key market trends
7.4.3 Competitive scenario
7.4.4 Key growth factors and opportunities
7.4.5 Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1 Quark Pharmaceuticals, Inc. (USA)

8.1.1 Company overview
8.1.2 Company snapshots
8.1.3 Strategic moves and developments

8.1.3.1 Principal Strategy
8.1.3.2 Secondary Strategy

8.1.4 SWOT Analysis

8.2 Alnylam Pharmaceuticals, Inc. (USA)

8.2.1 Company overview
8.2.2 Company snapshots
8.2.3 Business Performance
8.2.4 Strategic moves and developments

8.2.4.1 Principal Strategy
8.2.4.2 Secondary Strategy

8.2.5 SWOT Analysis

8.3 Dicerna Pharmaceuticals, Inc. (USA)

8.3.1 Company overview
8.3.2 Company snapshots
8.3.3 Business Performance
8.3.4 Strategic moves and developments
8.3.5 SWOT Analysis

8.4 Tekmira Pharmaceuticals Corp. (Canada)

8.4.1 Company overview
8.4.2 Company snapshots
8.4.3 Business Performance
8.4.4 Strategic moves and developments

8.4.4.1 Principal Strategy
8.4.4.2 Secondary Strategy

8.4.5 SWOT Analysis

8.5 Benitec Biopharma Limited (Australia)

8.5.1 Company overview
8.5.2 Company snapshots
8.5.3 Strategic moves and developments

8.5.3.1 Principal Strategy
8.5.3.2 Secondary Strategy

8.5.4 SWOT Analysis

8.6 Cenix BioScience GmbH (Germany)

8.6.1 Company overview
8.6.2 Company snapshots
8.6.3 Strategic moves and developments

8.6.3.1 Principal Strategy
8.6.3.2 Secondary Strategy

8.6.4 SWOT Analysis

8.7 Genzyme Corporation (USA) (A Sanofi Company)

8.7.1 Company overview
8.7.2 Company snapshots
8.7.3 Business performance
8.7.4 SWOT Analysis

8.8 Silence Therapeutics PLC (UK)

8.8.1 Company overview
8.8.2 Company snapshots
8.8.3 Business performance
8.8.4 Strategic moves and developments

8.8.4.1 Principal Strategy
8.8.4.2 Secondary Strategy

8.8.5 SWOT Analysis

8.9 Sirnaomics, Inc. (USA)

8.9.1 Company overview
8.9.2 Company snapshots
8.9.3 Strategic moves and developments

8.9.3.1 Principal Strategy
8.9.3.2 Secondary Strategy

8.9.4 SWOT Analysis

List of Figures

FIG. 1  TOP FACTORS IMPACTING RNA BASED THERAPEUTICS MARKET (2014-2020)
FIG. 2  TOP WINING STRATEGIES FOR RNA BASED THERAPEUTICS MARKET (2011-2013)
FIG. 3  TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENT
FIG. 4  PORTER’S FIVE FORCE ANALYSIS OF RNA BASED THERAPEUTICS MARKET
FIG. 5  VALUE CHAIN ANALYSIS OF RNA BASED THERAPEUTICS MARKET
FIG. 6  PIPELINE REVIEW OF RNA BASED THERAPEUTICS
FIG. 7  PATENT ANALYSIS BY GEOGRAPHIES (2011-2014)
FIG. 8  PATENT ANALYSIS BY GEOGRAPHIES BASED ON TECHNOLOGY(2011-2014)
FIG. 9  CLINICAL PHASE STATUS: RNAI THERAPIES
FIG. 10  CLINICAL PHASE STATUS: ANTISENSE THERAPIES
FIG. 11  GLOBAL RENAL DISEASES INCIDENCES: GLOBAL VIEW OF DIALYSIS PATIENTS (2012)
FIG. 12  GLOBAL CANCER INCIDENCES BASED ON COMMON CANCER TYPES (2012)
FIG. 13  NUMBER OF NEW INFECTIOUS DISEASE CASES IN UNITED STATES (2011)
FIG. 14  WHO ESTIMATES OF TUBERCULOSIS INCIDENCE BY WHO REGION (THOUSANDS) (2012)
FIG. 15  PREVALENCE OF OBESITY (2013); AGE 20 YEARS AND OLDER (%)
FIG. 16  TOP TEN COUNTRIES FOR NUMBER OF PEOPLE WITH DIABETES AGED BETWEEN 20-79 YEARS (2013, MILLION)
FIG. 17  SWOT ANALYSIS OF QUARK  PHARMACEUTICALS, INC.
FIG. 18  ALNYLAM’S NET REVENUE FROM RESEARCH COLLABORATORS (2012)
FIG. 19  SWOT ANALYSIS OF ALNYLAM PHARMACEUTICALS, INC.
FIG. 20  OPERATING EXPENSES OF DICERNA PHARMACEUTICALS INC. (2013)
FIG. 21  SWOT ANALYSIS OF DICERNA PHARMACEUTICALS, INC.
FIG. 22  TEKMIRA’S NET REVENUE FROM COLLABORATIONS AND CONTRACTS (2013)
FIG. 23  SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS CORPORATION
FIG. 24  SWOT ANALYSIS OF BENITEC BIOPHARMA LIMITED
FIG. 25  SWOT ANALYSIS OF CENIX BIOSCIENCE GMBH
FIG. 26  BUSINESS PERFORMANCE SANOFI S.A.  BY GEOGRAPHIES (2013)
FIG. 27  BUSINESS PERFORMANCE OF SANOFI S.A. BY BUSINESS SEGMENTS (2013)
FIG. 28  SWOT ANALYSIS OF SANOFI S.A.
FIG. 29  BUSINESS PERFORMANCE SANOFI S.A.  BY GEOGRAPHIES (2013)
FIG. 30  SWOT ANALYSIS OF SILENCE THERAPEUTICS PLC
FIG. 31  SWOT ANALYSIS OF SIRNAOMICS, INC.

List of Tables

TABLE 1  CONVENTIONAL VS RNA-BASED THERAPEUTICS
TABLE 2  TOP INVESTMENT POCKETS OF RNA BASED THERAPEUTICS MARKET (2013)
TABLE 3  LIST OF EMA DOCUMENTS AND GUIDELINES
TABLE 4  PATENT ANALYSIS BY GEOGRAPHIES(2010-2014)
TABLE 5  CLINICAL TRIALS FOR RNA BASED THERAPEUTICS
TABLE 6  PIPELINE RNA THERAPEUTICS AND THEIR SPECIFIC TARGET
TABLE 7  LIST OF STRATEGIC ALLIANCES FOR THE DEVELOPMENT OF RNA-BASED THERAPEUTICS
TABLE 8  LIST OF COMPANIES USING DIFFERENT RNA TECHNOLOGIES
TABLE 9  GLOBAL RNA BASED THERAPEUTICS MARKET BY TECHNOLOGIES, 2013 – 2020 ($MILLION)
TABLE 10  PRICES OF RNA PURIFICATION KITS
TABLE 11  PRICES OF LINEAR AMPLIFICATION KIT
TABLE 12  PIPELINE RESEARCH STATUS: RNAI THERAPIES
TABLE 13  PRICE CHART FOR SIRNA
TABLE 14  COMPANIES AND THEIR MIRNA TECHNOLOGIES
TABLE 15  PRICE CHART FOR MIRNA
TABLE 16  GLOBAL RNA INTERFERENCE (RNAI) TECHNOLOGY MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 17  GLOBAL RNA ANTISENSE TECHNOLOGY MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 18  GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 19  GLOBAL RNA BASED THERAPEUTICS CARDIOVASCULAR APPLICATIONS MARKET, BY GEOGRA PHY, 2013 – 2020 ($MILLION)
TABLE 20  GLOBAL RNA BASED THERAPEUTICS KIDNEY DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 21  GLOBAL CANCER INCIDENCE, MORTALITY AND PREVALENCE (2012)
TABLE 22  GLOBAL RNA BASED THERAPEUTICS ONCOLOGY APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 23  REGIONAL STATISTICS FOR HIV AND AIDS (2011)
TABLE 24  GLOBAL RNA BASED THERAPEUTICS INFECTIOUS DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 25  GLOBAL RNA BASED THERAPEUTICS METABOLIC DISORDERS APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 26  GLOBAL RNA BASED THERAPEUTICS OTHER  APPLICATIONS MARKET, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 27  GLOBAL RNA BASED THERAPEUTICS MARKET REVENUE, BY END USERS, 2013 – 2020 ($MILLION)
TABLE 28  RESEARCH COLLABORATIONS FOR RNA-BASED THERAPEUTICS
TABLE 29  REGION/COUNTRIES AND THEIR RESPECTIVE FUNDING AGENCIES
TABLE 30  GLOBAL RESEARCH MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 31  LIST OF RNA BASED THERAPEUTICS : APPROVED AND PHASE IIB & PHASE III CLINICAL TRIALS
TABLE 32  GLOBAL THERAPEUTICS MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 33  RNA DIAGNOSTIC COMPANIES AND THEIR CORE PRODUCTS
TABLE 34  GLOBAL DIAGNOSIS MARKET REVENUE, BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 35  GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 36  NORTH AMERICA RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 37  UNITED STATES: PIPELINE REVIEW
TABLE 38  EUROPE RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 39  ASIA- PACIFIC RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 40  LAMEA  RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 – 2020 ($MILLION)
TABLE 41  QUARK PHARMACEUTICALS, INC.
TABLE 42  ALNYLAM PHARMACEUTICALS SNAPSHOT
TABLE 43  DICERNA PHARMACEUTICALS, INC.SNAP SHOT
TABLE 44  TEKMIRA PHARMACEUTICALS CORPORATION SNAP SHOT
TABLE 45  BENITEC BIOPHARMA SNAPSHOT
TABLE 46  CENIX BIOSCIENCE SNAPSHOT
TABLE 47  GENZYME CORPORATION SNAPSHOT
TABLE 48  SILENCE THERAPEUTICS PLC SNAPSHOT
TABLE 49  SIRNAOMICS, INC SNAPSHOT